YBYana A. Bahareva

Yana A. Bahareva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yana A. Bahareva has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Analysis of SMN2 Splicing Activity and Protein Production Following In Vitro Treatment with the Generic Risdiplam Drug Vapromin® and the Reference Drug Evrysdi®

    by Olga Strizhakova, Andrei Pershin, Yana Bahareva, Aleksandr Kazarov, Ivan Lyagoskin, Evgenia Bocharova, Roman Anisimov, Yury Gladchenko, Natalia Kholod, Inessa Kirik, et al.

    Background/Objectives: Risdiplam is a low-molecular-weight small-molecule modifier of SMN2 pre-mRNA splicing that was developed for spinal muscular atrophy (SMA) therapy and approved for the treatment of SMA as Evrysdi® (Roche, Basel, Switzerland). Vapromin® is a generic drug produced by JSC GENERIUM. In order to evaluate its biological activity and compare different batches of the reference drug and generic risdiplam, we performed comprehensive in vitro procedures. It is important to emphasize that this study did not assess the bioequivalence of the medicinal products for the purpose of comparing the biopharmaceutical quality of the generic and reference products. Instead, this study was designed specifically to compare their biological activity using cells derived from SMA patients and a reporter cell line. Methods: The biological activity of generic risdiplam was compared with that of the reference drug by assessing increases in SMN protein production and the relative transcription level of SMN2 mRNA in fibroblasts from SMA donors. Additionally, Exon 7 inclusion efficiency was evaluated using a constructed reporter cell line. Results: Using primary dermal fibroblasts from SMA probands, we demonstrated a concentration-dependent relationship between risdiplam concentration and SMN2 FL and SMN2 Δ7 transcript levels. At a risdiplam concentration of 0.18 μM, the relative SMN2 full-length transcript levels reached a maximum, with a mean 2.5-fold increase observed for both Evrysdi® (Roche, Basel, Switzerland) and Vapromin®. In primary fibroblasts derived from three SMA patients, the 2 SD quality range for Evrysdi® (Roche, Basel, Switzerland) was 98.0–106.7% (σ(log RP) = 0.0092), and the activities of all Vapromin® batches fell within this range. Using the reporter cell line, the quality range for Evrysdi® (Roche, Basel, Switzerland) was 88.32–117.3% (σ = 0.0309), and the Vapromin® values also fell within this range. Conclusions: This study experimentally confirmed that the in vitro biological activity of the generic drug Vapromin® is comparable to that of Evrysdi® (Roche, Basel, Switzerland). Further research should be conducted to confirm bioequivalence between the two products.


  • Open Access

    Development and Validation of Cell-Based Bioassay for the Detection of Neutralizing Antibodies to Ocrelizumab in Human Serum Using Antibody-Dependent Cell-Mediated Cytotoxicity Test in a Reporter Cell Line Expressing FcγRIIIa

    by Olga Strizhakova, Grigory Poroshin, Andrei Pershin, Yana Bakhareva, Ivan Shevchenko, Ivan Lyagoskin, Rakhim Shukurov, Ravil Khamitov

    Background/Objectives: Ocrelizumab is a humanized monoclonal antibody targeting CD20, approved for the treatment of adult patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The neutralizing activity of anti-drug antibodies (ADAs), especially neutralizing ADAs (nADAs) activity, should be examined considering that it can alter pharmacokinetic (PK) and pharmacodynamic (PD) profiles, reduce drug efficacy, and lead to life-threatening adverse events. Methods: This article presents data on the development and validation of an assay for neutralizing anti-drug antibodies (nADA) based on ADCC reporter cells for the analysis of patient sera in the context of ocrelizumab clinical studies. Results: Critical steps and conditions to minimize assay variability were identified. The lower limit of detection was 549.6 ng/mL. The cutoff for nonspecific neutralization was determined as 19.7%. The presence of 0.37–3.0 μg/mL ocrelizumab in a biological sample enables the detection of 1.1–10.0 μg/mL polyclonal anti-ocrelizumab idiotype antibodies, respectively. Conclusions: The developed method can be used for immunogenicity studies of medicinal products containing ocrelizumab.

  • Open Access

    Comparative Immunogenicity of the Gam-COVID-Vac Vaccine under Intranasal and Intramuscular Administration

    by E. I. Katorkina, I. V. Lyagoskin, E. N. Bocharova, M. V. Bolotnikova, A. A. Borzov, N. V. Belskaya, A. E. Lisova, K. V. Ulyanova, N. K. Kudina, N. A. Belyanina, et al.

    Представлены результаты сравнительного исследования иммуногенности двухкомпонентной вакцины «Гам-КОВИД-Вак» производства АО «ГЕНЕРИУМ» (Россия) при разных путях введения мышам линии BALB/c (после введения первого или обоих компонентов). Об иммуногенности судили по изменению уровня антигенспецифических антител IgG и IgA в крови и бронхоальвеолярной жидкости, количеству Т-лимфоцитов, вырабатывающих IFN-γ при антигенной стимуляции, количеству антигенспецифических IFN-γ-продуцирующих CD4 и CD8 Т-лимфоцитов. Исследование показало, что интраназальное введение индуцировало развитие мукозального иммунитета, значительно превосходя качественно и количественно эффект внутримышечного введения (по количеству животных с антигенспецифическими антителами IgА и титру антител в сыворотке крови и бронхоальвеолярном лаваже); в то время как внутримышечное несколько превосходило эффект, полученный при интраназальном введении, по влиянию на общее количество продуцирующих IFN-γ CD8-лимфоцитов.

  • Open Access

    Optimization and validation of flow cytometry method for quantification of SARS-CoV-2 antigen-reactive human memory T cells

    by Olga M. Strizhakova, Andrey S. Pershin, Alexander A. Kazarov, Ivan V. Lyagoskin, Yana A. Bahareva, Alexander P. Vasil'EV, Yulia A. Nikonova, Irina Yu. Egorova, Rahim R. Shukurov, Ravil A. Khamitov, et al.

    A proper and representative monitoring of SARS-CoV-2 herd immunity including a long-term health impact on recovered patients and vaccinated individuals is of great importance. For this, a monitoring campaign should assesses both humoral and T-cell immune arms. Upon that, analyzing antigen specific-cell activation and cellular phenotype are informative. We developed a flow cytometry method for detection of intracellular IFN-producing antigen-reactive T cells after exposure of human peripheral blood mononuclear cells (PBMC) to SARS-CoV-2 virus antigens. The method was validated according to the following characteristics: sensitivity, specificity, precision, and robustness. We used positive samples from donors recovered from COVID-19 and negative samples from donors who had no contact with COVID-19 patients and lacking antibodies to SARS-CoV-2. All samples were tested by laboratory methods. Peripheral blood mononuclear cells were isolated from donor blood by centrifugation in a Ficoll density gradient. Specific T cells were stimulated with S-protein as well as N, M, ORF3a, and ORF7a protein peptides to count IFN-producing T cells by flow cytometer. The data were statistically analyzed. The area limited by ROC-curve and false positive rate (AUC) for CD4 and CD8 cells was from 0.97 to 1.00. Precision was considered acceptable because the coefficient of variation for all PBCM did not exceed 20%. Robustness was confirmed for frozen and freshly prepared PBMC samples. The thresholds levels to recognize immune and non-immune samples were defined for CD4-positive T-cells (0.029%) and CD8-positive T-cells (0.0640.068%). Also, acceptance criteria for positive and negative controls were defined. Based on the validation, the suitability of the method Evaluation of antigen-reactive T cells that produce intracellular IFN in response to SARS-CoV-2 virus antigens by flow cytometry was confirmed. The method allows for reliable data that was used to characterize standard control samples for internal quality control of TigraTest SARS-CoV-2 kits.